Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, VitaNova Life Sciences's enterprise value is $10.34 Mil.
VitaNova Life Sciences's EBITDA for the trailing twelve months (TTM) ended in Apr. 2026 was $0.01 Mil. Therefore, VitaNova Life Sciences's EV-to-EBITDA for today is 1,476.71.
The historical rank and industry rank for VitaNova Life Sciences's EV-to-EBITDA or its related term are showing as below:
VNOV'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -29325 Med: 2.83 Max: 1476.71
Current: 1476.71
During the past 10 years, the highest EV-to-EBITDA of VitaNova Life Sciences was 1476.71. The lowest was -29325.00. And the median was 2.83.
VNOV's EV-to-EBITDA is not ranked
in the Medical Distribution industry.
Industry Median: 8.565
vs VNOV: 1476.71
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
VitaNova Life Sciences (OTCPK:VNOV) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
VitaNova Life Sciences's PE Ratio (TTM) for today is calculated as:
VitaNova Life Sciences's share price for today is $1.38.
VitaNova Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.008.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, VitaNova Life Sciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VitaNova Life Sciences EV-to-EBITDA vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, VitaNova Life Sciences's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where VitaNova Life Sciences's EV-to-EBITDA falls into.
VitaNova Life Sciences's current Enterprise Value is $10.34 Mil.
VitaNova Life Sciences's EBITDA for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VitaNova Life Sciences (VNOV) has a EV-to-EBITDA of 1,476.71 as of Aug. 19, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on VitaNova Life Sciences. This is 52081% above median its historical median of 2.83.
Is VitaNova Life Sciences' EV-to-EBITDA too high?
VitaNova Life Sciences' current EV-to-EBITDA of 1,476.71 is 52081% above median its 10-year median of 2.83. The Medical Distribution industry median EV-to-EBITDA is 8.57. VitaNova Life Sciences' value of 1,476.71 is 17141.2% above this industry median. Overall, VitaNova Life Sciences has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does VitaNova Life Sciences' EV-to-EBITDA compare to HKPD and COSM?
VitaNova Life Sciences' EV-to-EBITDA of 1,476.71 can be compared against companies in the Medical Distribution industry. The industry median EV-to-EBITDA is 8.57. VitaNova Life Sciences' value of 1,476.71 is 17141.2% above this benchmark. While the company's 10-year median is 2.83 vs. the industry median of 8.57, VitaNova Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Distribution company?
The median EV-to-EBITDA among Medical Distribution companies is 8.57, based on 98 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. VitaNova Life Sciences's current EV-to-EBITDA of 1,476.71 is 17141.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on VitaNova Life Sciences. For the Medical Distribution industry, the median EV-to-EBITDA is 8.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VitaNova Life Sciences's current EV-to-EBITDA is 1,476.71, which is 52081% above median its own 10-year median of 2.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VitaNova Life Sciences stock overvalued right now?
VitaNova Life Sciences (VNOV) has a current EV-to-EBITDA of 1,476.71. The stock's GF Value™ is $5.95, compared to a current price of $1.38 — trading 76.8% below its estimated fair value. The current EV-to-EBITDA is 1,476.71, which is 52081% above median its 10-year median of 2.83 and 17141.2% above the Medical Distribution industry median of 8.57. VitaNova Life Sciences' overall GF Score™ is 51/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For VitaNova Life Sciences (VNOV), the current EV-to-EBITDA is 1,476.71 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is VitaNova Life Sciences (VNOV) Overvalued in 2026?
Based on GuruFocus' analysis, VitaNova Life Sciences stock appears to be undervalued.
The current stock price of $1.38 is trading 76.8% below its estimated GF Value™ of $5.95.
Key valuation signals for VNOV:
EV-to-EBITDA: 1,476.71 (52081% above median its 10-year median of 2.83)
GF Value™: $5.95 vs. price of $1.38 (76.8% below fair value)
Industry Position: 17141.2% above the Medical Distribution median
No single metric tells the full story. See the VNOV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
VitaNova Life Sciences Corp, formerly Yijia Group Corp provides business consulting services to domestic and international customers. The Company provides consulting services to its clients with regards to funding and other financial matters.The company's operating segments are The consulting services Segment mainly provides consulting advisory services in management, business, accounting and finance; and the Healthcare Segment mainly provides healthcare products and health consultation services to customers. The sale and distribution of healthcare products, such as Nicotinamide Riboside capsules, has only one performance obligation under the fixed-fee arrangements. and the majority of its revenue generates from Sales of healthcare products.
51GF Score
Get the complete analysis for VNOV
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VNOV has been successfully added to your 
